In the oral presentation, entitled "Selective Targeting of Point Mutations by Third Generation Antisense Oligonucleotides," Reina Improgo, Ph.D., Research Scientist of Idera's Discovery Team presented an overview of the novel mechanism of action of 3GA technology.
Based on the specificity in targeting RNA the data indicates that 3GA could be used to successfully treat diseases that require allele-specificity.
Additionally, Fugang Zhu, Ph.D. and Wayne Jiang, M.D., Ph.D., scientists from Idera's Discovery Team, presented a poster entitled, "Third generation antisense (3GA) targeting NLRP3 for the treatment of inflammatory disorders."
In the presentation, they showed that 3GA targeting NLRP3 led to the suppression of the NLRP3 mRNA and protein and inhibition of the downstream cascade, including IL-1 and IL-18.
The data also demonstrated that 3GA targeting of NLRP3 resulted in marked improvement in disease-associated parameters in both interstitial cystitis and uveitis preclinical models.